A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model
Phase of Trial: Phase I/II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs PC-786 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Pulmocide
- 15 May 2018 Status changed from active, no longer recruiting to completed.
- 26 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 26 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.